Elemental Impurities in Animal Drug Products
Questions and Answers

Guidance for Industry

Draft Guidance

*This guidance is being distributed for comment purposes only.*

Submit comments on this guidance by the date provided in the *Federal Register* notice announcing the availability of the draft guidance. Submit electronic comments to [https://www.regulations.gov](https://www.regulations.gov). Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For further information regarding this document, contact Michael Brent, Center for Veterinary Medicine (HFV-140), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 240-402-0647, e-mail: michael.brent@fda.hhs.gov.

Additional copies of this guidance document may be requested from the Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, and may be viewed on the Internet at either [https://www.fda.gov/AnimalVeterinary/default.htm](https://www.fda.gov/AnimalVeterinary/default.htm) or [https://www.regulations.gov](https://www.regulations.gov).

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Veterinary Medicine
March 2018
Table of Contents

I. INTRODUCTION ................................................................................................. 3
II. BACKGROUND AND SCOPE ........................................................................... 3
III. RECOMMENDATIONS ...................................................................................... 4

Q1. What elements should be evaluated? .............................................................. 4
Q2. Is it necessary to test the drug product for elemental impurities? ................. 4
Q3. How should raw materials be evaluated for their potential to introduce elemental impurities into the finished drug products? ........................................... 4
Q4. How should the potential for the container closure and manufacturing equipment to leach elemental impurities into the drug product be addressed? 5
Q5. Can a non-specific test, such as the test for heavy metals previously described in USP <231>, be used to test a raw material, or should instrumental methods, such as those described in USP <233> be used? ........................................ 5
Q6. For approved products, should we continue to perform the USP <231> test for heavy metals where it is included in the approved specifications? .......... 6
Q7. Some USP monographs for raw materials contain limits for specific elements, and in some cases a different general chapter, such as USP <211>, Arsenic, or USP <251>, Lead, is referenced. Do these limits apply to veterinary products? ................................................................. 6
Q8. If a certificate of analysis for an excipient or drug substance contains test results for specific elements using an instrumental method per USP <233>, do these tests need to be confirmed as part of vendor qualification? ........... 6
Q9. When specified elements are known to be present in one or more of the excipients or the drug substance, how should the elemental impurity daily exposure from the drug product be assessed? ........................................... 6
Q10. Even in cases where the COA includes results for elemental impurities and a specific risk factor has been identified, often the excipient or drug substance make up a small percentage of the drug product, or the COA results demonstrate that the elements are controlled at low levels. Is there a threshold at which we would not be expected to confirm the COA results? ............. 7
Q11. Does this guidance apply to Type A medicated articles? .......................... 7
Q12. What if the drug product contains elements that are for therapeutic benefit? .. 7
Q13. When is it necessary to re-assess the risk for the drug product? ................ 7
Q14. What information should be submitted to the file? ..................................... 8

IV. Appendix I – Example decision tree for the components of the animal drug product. ................................................................................................................. 9
Elemental Impurities in Animal Drug Products
Questions and Answers

Guidance for Industry

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance is intended to assist sponsors of animal drug products in addressing changes in the United States Pharmacopeia (USP) requirements for the control of elemental impurities in drug products marketed in the United States.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency’s guidances means that something is suggested or recommended, but not required.

II. BACKGROUND AND SCOPE

USP General Chapter <231>, Heavy Metals, will be deleted with the implementation of General Chapters <232>, Elemental Impurities – Limits, and <233>, Elemental Impurities – Procedures. While USP <232> will not apply to animal drug products, the Center for Veterinary Medicine (CVM) expects sponsors of animal drug products to continue to apply a risk-based control strategy for elemental impurities and establish appropriate acceptance criteria and test methods for elemental impurities where necessary. Ensuring that elemental impurities in the final drug product are controlled within safe limits remains the responsibility of the sponsor of the animal drug product.

This document provides recommendations to sponsors regarding the control of elemental impurities in animal drug products, including all dosage forms and routes of administration. The information to be maintained on-site and information to be submitted to CVM is also clarified. The submission of information regarding components and composition, as well as manufacturing methods, facilities, and controls is required under 21 CFR 514.1(b)(4) and (5) for new animal drug applications and under section 512(n)(1)(G) of the Federal Food, Drug, and Cosmetic Act for abbreviated new animal drug applications. The submission of manufacturing changes to an approved application is required under 21 CFR 514.8(b)(1)(i).

Approaches other than those set forth in this guidance may be applicable and acceptable.
III. RECOMMENDATIONS

CVM recommends that animal drug product sponsors perform a thorough evaluation of the component materials of the drug product, including communication with the suppliers of sourced materials, and an evaluation of the manufacturing process for the drug product to identify risk factors that could potentially lead to significant levels of one or more elemental impurities in the drug product. CVM will only expect test methods and limits for elemental impurities in cases where a specific risk is identified based on the evaluation of the raw materials, primary packaging, and manufacturing process for the product.

This section includes CVM’s answers to the following questions regarding control of elemental impurities.

Q1. What elements should be evaluated?

A. At a minimum, a risk assessment should evaluate if arsenic, lead, mercury, cadmium, and any additional elements used in the excipient, drug substance, and drug product manufacturing process, such as catalysts, could be introduced into the finished drug product.

Q2. Is it necessary to test the drug product for elemental impurities?

A. CVM recommends that animal drug product sponsors evaluate the raw materials, primary packaging, and manufacturing process to identify any risk factors that could potentially lead to significant levels of one or more elemental impurities in the drug product (see Q3 and Q4 below). Some examples of risk factors for introduction of elemental impurities into the drug product include the use of a catalyst or inorganic reagent in the manufacture of a raw material or the drug product, and the use of inorganic raw materials, including mined materials, in the drug product formulation. See International Council for Harmonisation (ICH) Q3D, Guideline for Elemental Impurities,¹ for more information on performing risk assessments. In cases where a specific risk factor has been identified based on this assessment, CVM would expect a test method and limit for elemental impurities in either the raw material or the drug product to ensure that they are adequately controlled (see Q9 and Appendix I for more information).

Q3. How should raw materials be evaluated for their potential to introduce elemental impurities into the finished drug products?

A. The considerations may include, but are not limited to:

   • Knowledge of the raw material (drug substance and excipients) source and production process;

The quality of any water used in the raw material or drug product manufacturing processes;

- Supplier information and Certificate of Analysis (COA) data;

- Published data;

- Test results generated by the animal drug product sponsor.

The principles described in ICH Q9, Quality Risk Management, and ICH Q3D should be considered. Control approaches should be proportional to the level of risk (see Q5, Q9, Q10, and Appendix I).

Q4. How should the potential for the container closure and manufacturing equipment to leach elemental impurities into the drug product be addressed?

A. CVM considers the risk of elemental impurities from the container closure to be low in most cases. If the supplier certifies that the materials of construction of the primary packaging meet the applicable requirements of the USP and the U.S. Code of Federal Regulations (CFR), the animal drug product sponsor will not be asked to confirm the COA results for extractable metals. If a statement or data are unavailable from the manufacturer of the primary packaging regarding elemental impurities, CVM recommends performing at a minimum a test for heavy metals, such as the procedure previously described in USP <231>, for containers used for liquid and semi-solid dosage forms. The probability of elemental leaching into solid dosage forms is minimal and does not require further evaluation in the risk assessment. If the primary container closure components are expected to introduce elemental impurities into the drug product at levels that present a safety concern, adequate controls should be in place or testing of the drug product may be necessary.

CVM considers the risk from manufacturing equipment to be low in most cases. Unless an unusual amount of equipment corrosion or wear is anticipated as a result of the manufacturing process, no further assessment is expected.

Q5. Can a non-specific test, such as the test for heavy metals previously described in USP <231>, be used to test a raw material, or should instrumental methods, such as those described in USP <233> be used?

A. Procedures with specificity for individual elements, such as atomic absorption spectroscopy or the procedures described in USP <233>, should be used where controls for individual elements are necessary based on the risk assessment (see Appendix I for additional guidance). CVM will continue to accept non-specific tests, such as the procedures previously described in USP <231>, where this is supported by the risk assessment. For example, a heavy metals test may be justified and maintained as a non-

specific control for elemental impurities in inorganic excipients that account for a small fraction of the drug product composition.

Q6. For approved products, should we continue to perform the USP <231> test for heavy metals where it is included in the approved specifications?

A. The decision to maintain or delete the test should be based on the risk assessment for the product. As part of the decision making process, the animal drug product sponsor should reevaluate whether a non-specific test, such as the heavy metals test from <231>, is adequate based on the level of risk. If the test method will be maintained, it should be included in the file since the chapter will be deleted from the USP, and the reference to USP <231> will no longer apply. If, based on the risk assessment, the heavy metals test is deemed unnecessary, the test and limit may be deleted, and the change may be reported in the next Minor Changes and Stability Report (MCSR) with a risk-based justification.

Q7. Some USP monographs for raw materials contain limits for specific elements and in some cases a different general chapter, such as USP <211>, Arsenic, or USP <251>, Lead, is referenced. Do these limits apply to veterinary products?

A. At a minimum, these materials should continue to meet the requirements in the monograph, including the limits for specified elements where applicable. An instrumental method consistent with those described in USP <233> may be used as an alternative to the referenced procedure.

Q8. If a certificate of analysis for an excipient or drug substance contains test results for specific elements using an instrumental method per USP <233>, do these tests need to be confirmed as part of vendor qualification?

A. This depends on the risk assessment. Communication with the supplier regarding the reason for including limits for specific elements is recommended. The results should be confirmed by the animal drug product sponsor only when deemed necessary by the risk assessment (see Q10 and Appendix I).

Q9. When specified elements are known to be present in one or more of the excipients or the drug substance, how should the elemental impurity daily exposure from the drug product be assessed?

A. The daily exposure to the elements should be calculated based on the supplier’s limit, the composition of the excipient or drug substance in the drug product, and the maximum daily dose. If the same element may be introduced by more than one component of the drug product, the total exposure should be calculated. CVM considers the Permitted Daily Exposures (PDEs) established in ICH Q3D acceptable for the safety of animal drug products. The calculated elemental impurity daily exposure should result in a level equal to or below the ICH Q3D PDE; however, CVM recognizes that the PDEs in ICH Q3D are for humans. If the calculated elemental impurity content of the animal drug product
exceeds the PDE in ICH Q3D, the animal drug product sponsor may provide a justification or contact CVM to discuss the product and veterinary-specific considerations.

Q10. Even in cases where the COA includes results for elemental impurities and a specific risk factor has been identified, often the excipient or drug substance make up a small percentage of the drug product or the COA results demonstrate that the elements are controlled at low levels. Is there a threshold at which we would not be expected to confirm the COA results?

A. If the elemental impurity content listed on the COA will lead to a daily exposure that is not more than 30% of the PDE, the risk from the raw material can usually be considered below the threshold at which additional testing by the drug product manufacturer is necessary (see Appendix I) and confirmation of the COA values for elemental impurities will not be requested. If the 30% threshold will be applied, the total daily exposure should not exceed 30% of the PDE in cases where the same element may be introduced by multiple components of the drug product.

If the 30% threshold is exceeded but the elements are below the PDE, the drug product manufacturer should confirm the COA results for vendor qualification, or, alternatively, test every lot of the drug product to ensure that the element does not exceed the PDE. A test with specificity for the individual target elements should be used unless an alternative approach can be justified.

Q11. Does this guidance apply to Type A medicated articles?

A. Yes. When a specific risk factor has been identified that may lead to introduction of elemental impurities into the Type A medicated article, any calculations of the daily exposure should take into account the ultimate dilution of the Type A to produce a medicated feed.

Q12. What if the drug product contains elements that are for therapeutic benefit?

A. This guidance does not apply to elements that are present in a form that is for therapeutic benefit (e.g., as part of the active pharmaceutical ingredient).

Q13. When is it necessary to reassess the risk for the drug product?

A. The potential sources of elemental impurities in the drug product should be reevaluated where necessary throughout the product lifecycle, for example:

- With changes to the components and composition of the drug product;
- With changes to the drug product manufacturing process;
- With changes to the drug product manufacturing facility or equipment;
With changes to the source or manufacturing process for the drug substance or excipients;

With changes to the primary packaging components.

Q14. What information should be submitted to the file?

A. Submit any new test methods and limits for elemental impurities. If one of the compendial procedures described in USP <233> is used, the animal drug product sponsor may simply reference that chapter for the method. For approved products, this information can be provided in an annual MCSR unless a new testing facility is requested. A new testing facility should be reported in a supplement according to CVM Guidance for Industry #83, “Chemistry, Manufacturing, and Controls Changes to an Approved NADA or ANADA.” The risk assessment, any calculations, and any method validations, where applicable, should be kept on site to provide to an investigator upon request (see 21 CFR part 211). CVM may request additional information on a case-by-case basis.

---

IV. Appendix I – Example decision tree for the components of the animal drug product.

Based on a thorough assessment of the component materials, including the primary packaging, has a potential risk been identified that could lead to the introduction of elemental impurities into the drug product?

NO

A test for elemental impurities is not necessary. Reevaluate the risk throughout the product lifecycle as necessary.

YES

Has the supplier of the material characterized the content of the elements in the material and reported their findings?

YES

Is each element controlled below a level that ensures the content in the drug product will not exceed 30% of the PDE?

NO

Confirm the COA results for vendor qualification. A test method with specificity for the individual target elements should be used unless an alternative method can be justified.

DO the test results and the supplier's limit ensure that the elements will be controlled below the PDE?

YES

Perform reduced testing or discontinue routine testing with justification.

NO

Test each incoming lot of raw material, or each lot of drug product to confirm that the content in the drug product will not exceed the PDE.

NO

Perform reduced testing or discontinue routine testing with justification.

YES

Test incoming lots to confirm that the elements remain within a suitable limit. A test method with specificity for the individual target elements should be used.

DO the test results demonstrate that the elements are controlled below a level that ensures the content in the drug product will not exceed 30% of the PDE?